Meta-analysis confirms BCL2 is an independent prognostic marker in breast Cancer by Callagy, Grace M et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
Meta-analysis confirms BCL2 is an independent prognostic marker 
in breast cancer
Grace M Callagy*1, Mark J Webber1, Paul DP Pharoah2 and Carlos Caldas3
Address: 1Department of Pathology, National University of Ireland, Galway, Clinical Science Institute, Costello Road, Galway, Ireland, 2Cancer 
Research-UK Department of Oncology, Cancer Research-UK Genetic Epidemiology Unit and EPIC, Strangeways Research Laboratory, Worts 
Causeway, Cambridge CB1 8RN, UK and 3Department of Oncology, University of Cambridge and Cancer Research-UK Cambridge Research 
Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK
Email: Grace M Callagy* - grace.callagy@nuigalway.ie; Mark J Webber - mark.webber@nuigalway.ie; Paul DP Pharoah - paul1@srl.cam.ac.uk; 
Carlos Caldas - cc234@cam.ac.uk
* Corresponding author    
Abstract
Background: A number of protein markers have been investigated as prognostic adjuncts in
breast cancer but their translation into clinical practice has been impeded by a lack of appropriate
validation. Recently, we showed that BCL2 protein expression had prognostic power independent
of current used standards. Here, we present the results of a meta-analysis of the association
between BCL2 expression and both disease free survival (DFS) and overall survival (OS) in female
breast cancer.
Methods: Reports published in 1994–2006 were selected for the meta-analysis using a search of
PubMed. Studies that investigated the role of BCL2 expression by immunohistochemistry with a
sample size greater than 100 were included. Seventeen papers reported the results of 18 different
series including 5,892 cases with an average median follow-up of 92.1 months.
Results: Eight studies investigated DFS unadjusted for other variables in 2,285 cases. The relative
hazard estimates ranged from 0.85 – 3.03 with a combined random effects estimate of 1.66 (95%CI
1.25 – 2.22). The effect of BCL2 on DFS adjusted for other prognostic factors was reported in 11
studies and the pooled random effects hazard ratio estimate was 1.58 (95%CI 1.29–1.94). OS was
investigated unadjusted for other variables in eight studies incorporating 3,910 cases. The hazard
estimates ranged from 0.99–4.31 with a pooled estimate of risk of 1.64 (95%CI 1.36–2.0). OS
adjusted for other parameters was evaluated in nine series comprising 3,624 cases and the
estimates for these studies ranged from 1.10 to 2.49 with a pooled estimate of 1.37 (95%CI 1.19–
1.58).
Conclusion: The meta-analysis strongly supports the prognostic role of BCL2 as assessed by
immunohistochemistry in breast cancer and shows that this effect is independent of lymph node
status, tumour size and tumour grade as well as a range of other biological variables on multi-variate
analysis. Large prospective studies are now needed to establish the clinical utility of BCL2 as an
independent prognostic marker.
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Breast cancer is a heterogenous disease whose behaviour
is determined by the molecular characteristics of the
tumour. In clinical practice, we rely on clinico-pathologi-
cal features to predict tumour behaviour and patient out-
come. These are powerful independent prognosticators
[1,2] but are imperfect and represent only crude measures
of the biological behaviour of a tumour. The power of
these factors can be increased when they are used in com-
bination e.g. the Nottingham Prognostic Index (NPI) [1]
but they cannot predict outcome for all patients [3-5] and,
as a result, many patients receive unnecessary treatment.
In the last 30 years, intensive efforts have been made to
identify tools to improve prognostication. These range
from biological markers to computer-based algorithms
such as ADJUVANT! [6] that incorporate clinico-patho-
logical and biological features. Early immunohistochemi-
cal studies identified a plethora of biological markers that
can be triaged into categories based on the strength of evi-
dence supporting their prognostic role [7]. However,
twenty years on only steroid hormone receptors and
HER2 are used in clinical practice. The translation of these
results has in part been impeded by a lack of robustness of
the original research findings. Many studies were small
and false positives are the result of a combination of low
statistical power and publication bias. Furthermore, many
prognostic markers are correlated and small studies have
limited power to show independence of effects of novel
markers in multivariate analyses.
Prognostic gene-based signatures have been reported with
the claim that they out-perform current standards [8,9]
although this has been questioned [10-12]. While prom-
ising, inconsistencies relating to quality control, tissue
handling, sample size and data analysis need to be
addressed before the clinical utility of gene-based prog-
nostic signatures can be established. Two prospective clin-
ical trials of prognostic gene signatures are now ongoing
[13,14] and, it is hoped, these will provide insight into the
utility of widespread gene expression profiling as clinical
tools.
A complementary approach uses a limited number of
immunohistochemical markers as surrogates for the gene-
based signatures. The 'intrinsic subtypes' [15-17] have
been reproduced repeatedly in this way and this method-
ology is likely to be a more realistic approach for routine
diagnostic application [18-20]. In order to have clinical
application, it is paramount that any marker shows good
and poor prognostic groups independently of currently
used standards or markers at stringent levels of statistical
significance. With this in mind, we recently evaluated a
panel of 13 biomarkers by immunohistochemistry (IHC)
in a series of over 700 breast cancers and validated the
findings in a second consecutive series of 983 cases on a
tissue micro-array (TMA) [21]. The panel included pro-
teins whose genes were differentially expressed in the
intrinsic subsets defined by microarray profiling [15,16].
We expected that such a panel would have greater prog-
nostic power than any one individual marker but the
results showed otherwise: only the anti-apoptotic protein
BCL2 was required to predict overall survival independent
of traditional parameters in both series. Furthermore
BCL2 added to the prognostic power of the NPI.
The BCL2 protein is a member of the bcl family that regu-
late apoptosis. Its tumorigenic potential has been demon-
strated in animal models [22] and is supported by the
finding of over-expression of BCL2 in a variety of tumours
and in lymphomas in which BCL2 acts as an oncogene
[23,24]. In many solid organ tumours, including breast
cancer, BCL2 paradoxically appears to exert a tumour sup-
pressor effect, where its expression is associated with
favourable prognostic features e.g. low grade, oestrogen
receptor (ER)-positivity and good outcome [21]. This has
been a consistent finding in most reports but the associa-
tion with outcome was limited to univariate analysis in
many.
The aim of this study was to evaluate the prognostic role
of BCL2 in breast cancer by sytematically reviewing the
available evidence. To this end, we identified all pub-
lished reports that assessed the relationship between
BCL2 and outcome in breast cancer and performed a
meta-analysis using standard statistical techniques.
Methods
Reports investigating the prognostic role of BCL2 in breast
cancer were selected for review using a search of PubMed
from 1994–2006 using the following criteria: '(bcl-2 and
breast) AND (prognosis* [Title/Abstract] OR (first [Title/
Abstract] AND episode [Title/Abstract]) OR cohort [Title/
Abstract])' and also '(bcl-2 and breast) AND (incidence
[MeSH:noexp] OR mortality [MeSH Terms] OR follow up
studies [MeSH:noexp] OR prognos* [Title/Abstract] OR
predict* [Title/Abstract] OR course* [Text Word])' limited
to the English language. Three hundred and thirty three
citations were retrieved. Eligible reports were those that
examined the association between expression of BCL2 by
IHC and either overall survival (OS) and/or disease free
survival (DFS) in a clinical series of invasive breast cancer.
Reports considered ineligible for the meta-analysis were
reviews; those of in situ carcinoma or precursor lesions or
of only male breast cancer; those that used cell lines or
techniques other than IHC; and reports where either OS
or DFS were not used as clinical endpoints; or where the
association between another marker and outcome was
being examined and data for BCL2 was not presented.
Authors that published multiple reports on a single seriesPage 2 of 10
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also searched by hand.
Fifty-three eligible studies were identified. Small studies
are more prone to publication bias and failure to report a
hazard ratio (HR) can be taken as an indicator of study
quality [25]. We therefore included the seventeen studies
that were based on at least 100 patients and had also
reported an estimate of the HR [21,26-41]. The remaining
36 reports (Additional files 1 and 2) included 11 reports
that were either based on a small number of cases (≤ 100)
or were larger studies that did not report a HR but did pro-
vide sufficient data to estimate the HR according to the
method of Parmer et. al. [42]. These were analysed sepa-
rately to determine if these studies would introduce signif-
icant bias [43-53]. The remaining 25 studies, including
nine using small series, provided insufficient data for
analyses and were excluded (Additional files 1 and 2).
Design of the meta-analysis
Pooled estimates of the HRs were obtained using both
fixed-effect and random-effects meta-analysis using the
inverse-variance weighting method based on published
confidence intervals for the HRs [54]. For those studies
that did not report the HR but did provide sufficient infor-
mation on survival by BCL2 status the we estimated the
HR and confidence intervals according to the method of
Parmer et al. [42].
In one report [27], the upper confidence limit for the uni-
variate HR was clearly incorrect and inconsistent with the
lower confidence limit. The variance for this HR was esti-
mated based on the lower confidence limit only. Statisti-
cal heterogeneity between studies was assessed using the
among-study variance (s2) and the statistic I2 [55]. A fun-
nel plot and Egger's regression test for funnel plot asym-
metry [56] were used to look for the presence of a small-
study effect that might be due to publication bias.
In many studies, in addition to univariate analysis, the
risks were adjusted for other prognostic factors. We per-
formed separate analyses based on adjusted and unad-
justed HRs for both DFS and OS. For the purposes of the
analysis we converted all hazard ratios to a comparison of
BCL2 negative tumours with BCL2 positive tumours.
All analyses were carried out using Stata version 9 (Stata
Corporation, College Station, TX, USA).
Results
Seventeen papers reporting 18 large case series with com-
plete statistical data were included in the main analyses.
These evaluated the role of BCL2 as a predictor of OS or
DFS in 5,892 cases of breast cancer (Additional files 3 and
4). Median follow-up ranged from 0.2 to 472 months
(average 92.1 months). In total, 2,619 cases of node-neg-
ative disease and 3,963 cases of node-positive disease
were analysed. In 333 cases, nodal status was either
unknown or not indicated. Five of the 18 series comprised
consecutive cases unselected for specific characteristics
[21,29,31,33,39]. The remainder consisted of cases that
were either accrued onto clinical trials [21,32,35,37] or
selected according to defined eligibility criteria i.e. node-
negative [30,41] or node-positive [26,28,34,36,38,40]
disease, or tumour size [27]. Unfortunately, the number
of studies was too small for formal meta-analysis for each
of these end-points.
Fourteen studies reported on the effect of BCL2 on DFS of
which three reported only unadjusted [32,34,40] and six
reported only multivariate adjusted [29,30,33,36,37,39]
hazards and five reported both [26,27,35,38,41]. Where
multivariate analysis was performed the parameters
included varied. Clinico-pathological variables were
incorporated in most analyses with the following excep-
tions. Tumour size was excluded in two reports [35,37].
Nodal status was omitted in five studies [26,30,35,37,41]
although these were selected series that consisted entirely
of either node positive [26], node negative [30,41] or met-
astatic disease [35,37]. Tumour grade was also excluded in
five reports [26-28,37,38]. The other biomarkers assessed
varied with the exception of steroid hormone receptor sta-
tus, which was incorporated in the majority of analyses
(except [27,29]). p53 was included as a co-variable in 11
studies [21,26-28,31-34,37,39,40] and HER2 in three
[21,26-28,31-34,37,39,40]. A monoclonal antibody to
assess BCL2, either from Dako (Clone 124) [21,26-28,31-
34,37,39,40], Novacastra [29] or Dakopatts [30,36,38,41]
was used by most investigators. A polyclonal antibody
was used in one study [35]. Cytoplasmic staining was
scored using a dichotomous scoring system in all studies
with a cut-off for positive status between 10% and 40%.
Berardo et al. [34] applied both continuous and dichoto-
mous system and showed that the former was associated
with independent significance but not the latter.
Eight studies including 2,285 patients reported the effect
of BCL2 expression on DFS in analyses unadjusted for
other risk factors (Figure 1, Table 1). The unadjusted HR
estimates for DFS from these studies ranged from 0.85 –
3.03 and all but one of these was significant at a nominal
p < 0.05. The pooled random effects estimate was 1.66
(95% CI = 1.25 – 2.22). However, there was evidence for
significant heterogeneity amongst the studies (Q = 22.4, 7
degrees of freedom (df), p = 0.002), which might be
expected given the difference in populations being stud-
ied and experimental methods used. Five studies
[26,34,35,38,41] included node-positive disease only
accounting for 1,659 cases. Notwithstanding that, the het-
erogeneity was largely due to the study reported by Mot-Page 3 of 10
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Table 1: Results of meta-analysis of expression of Bcl-2 and outcome in Breast Cancer.
Endpoint and meta-analysis model Estimate of Relative Hazard Homogeneity Test
(95% CI) p Q (df) p
Unadjusted Disease-Free Survival (8 studies, n = 2285)
Fixed 1.5 (1.3–1.7) <0.001 22.4 (7) 0.002
Random 1.7 (1.3–2.2) <0.001
Fixed * 1.7 (1.5–2.0) <0.001 6.6 (6) 0.360
Random* 1.7 (1.5–2.1) <0.001
Adjusted Disease-Free Survival (11 studies, n = 2128)
Fixed 1.5 (1.3–1.7) <0.001 17.2 (10) 0.07
Random 1.6 (1.3–2.0) <0.001
Unadjusted Overall Survival (8 studies, n = 3910)
Fixed 1.6 (1.4–1.7) <0.001 17.5 (7) 0.015
Random 1.6 (1.4–2.0) <0.001
Fixed * 1.6 (1.5–1.8) <0.001 10.0 (6) 0.126
Random* 1.7 (1.5–2.0) <0.001
Adjusted Overall Survival (9 studies, n = 3624)
Fixed 1.3 (1.2–1.4) <0.001 15.5 (8) 0.050
Random 1.4 (1.2–1.6) <0.001
* values after exclusion of the study by Motolesse et al. [31] (n = 157)
Funnel plot of the combined relative hazard from the random effects models for disease free survival in BCL2 negative cases compared t  BCL2 positive cases in univariate analysisigure 1
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better outcome for BCL2 negative tumours. After the
exclusion of the latter, the pooled estimate of HR was 1.74
(95%CI = 1.46–2.07) with no significant heterogeneity
(Q = 6.6, 6 df, p = 0.36). There was no evidence for publi-
cation bias (p = 0.14). Eight studies were excluded from
the primary analysis because they were small or because
the HR was not reported but could be estimated from the
data presented [43-48,52,53]. The pooled HR for these
studies was 2.11 (95%CI = 1.62 – 2.77). This is signifi-
cantly different from the estimate for the other studies (p
= 0.02) suggesting, as predicted, a substantial bias in the
HR estimates for the smaller studies and those with less
completely reported data. If, however, all studies were
analysed together the pooled HR estimate was 1.59
(95%CI = 1.41 – 1.81).
Eleven studies including 2,105 patients reported the
effects of BCL2 on DFS adjusted for other prognostic fac-
tors [26,27,29,30,33,35-39,41] (Table 1). The adjusted
HR estimates were generally close to one but ranged from
1.10 to 3.26. In five of these studies incorporating 950
cases, BCL2 was an independent predictor of DFS. The
pooled random effects HR estimate for these studies was
1.58 (95%CI = 1.29–1.94) without evidence for signifi-
cant heterogeneity between the studies (Q = 17.2, 10 df,p
= 0.07) or publication bias (p = 0.78). Four of the studies
that failed to show an independent association between
BCL2 and DFS used the Dakopatts or a polyclonal anti-
body.
The effect of BCL2 expression on OS was evaluated in 12
studies in 11 reports (Table 1). HRs were unadjusted in
three of these [32,34,40] and adjusted for other variables
in four [28,36,37,39] and both unadjusted and adjusted
HRs were given in four other reports [21,27,31,41]. The
eight studies from seven reports [21,27,31,41] incorporat-
ing 3,910 cases where the expression of BCL2 was unad-
justed for other variables produced hazard estimates
ranging from 0.99–4.31 (Figure 2), of which 6 were statis-
tically significant with a pooled estimate of risk of 1.64
(95%CI = 1.36–1.97). There was evidence of statistical
heterogeneity (Q = 17.5, 7 df, p = 0.015) that again was
virtually entirely due to the contribution of the report by
Funnel plot of the combined relative hazard from the random effects models for overall survival for BCL2 negative cases com-pared to BCL-2 positive cases in univariate analysisigure 2
Funnel plot of the combined relative hazard from the random effects models for overall survival for BCL2 neg-
ative cases compared to BCL-2 positive cases in univariate analysis.
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change in the HR (pooled estimate 1.73, 95%CI = 1.48–
2.02) and no evidence for heterogeneity (Q = 9.98, 6 df, p
= 0.13) or publication bias (p = 0.87).
Six studies were excluded from the primary analysis
because they were small or because the HR was not
reported but could be estimated from the data presented
[44,48-52]. The pooled HR for these studies was 3.42
(95%CI = 2.41 – 4.86). This is significantly different from
the estimate for the other studies (p < 0.001), again sug-
gesting a substantial bias in the HR estimates for the
smaller studies. If, however, all studies were analysed
together the pooled HR estimate was 1.99 (95%CI = 1.62
– 2.45).
Nine series comprising 3,624 cases were used for the
meta-analysis of the expression of BCL2 on OS adjusted
for other parameters [21,27,28,31,36,37,39,41]. BCL2
was an independent predictor of outcome in four of these
[21,36,39] totalling 2,190 cases. A narrow range of esti-
mates was observed from 1.10 to 2.49 with a pooled esti-
mate of 1.37 (95%CI = 1.19–1.58). There was borderline
evidence of heterogeneity between the studies (Q = 15.48,
8 df, p = 0.05) and evidence of publication bias (p =
0.022).
Discussion
The published data incorporating 5,892 cases strongly
support the prognostic role of BCL2 as assessed by IHC in
breast cancer showing that it is associated with both DFS
and OS (pooled HR estimates of 1.66 and 1.64 respec-
tively). These effects were slightly attenuated but still sig-
nificant in multivariate analyses (adjusted HRs of 1.58
and 1.37 for DFS and OS respectively), showing that this
effect is independent of lymph node status, tumour size
and tumour grade as well as a range of other biological
variables on multivariate analysis.
It is possible that the result of the meta-analysis could
have been influenced by differences between the 18 stud-
ies. The finding of study heterogeneity in HR estimates is
unsurprising and, even though the study by Mottolese et
al. accounted for much of the heterogeneity for DFS, there
were substantial differences between the other studies that
could have influenced the result. Different cohorts of
patients and treatment regimes were used. Five studies
used unselected consecutive series [21,29,31,33,39] and
these patients were managed according to standard treat-
ment protocols. In all of these reports, BCL2 was an inde-
pendent predictor of either DFS [29,33,39] or OS
[21,31,39] on multivariate analyses. Treatments varied
where cases were part of a clinical trial [21,26,32,35,37]
although BCL2 was still an independent predictor of DFS
and OS in the majority ([26,37] and [21,37] respectively).
The cause of the heterogeneity from the study of Mot-
tolese et al. is unclear. The series was part of a clinical trial
that examined the influence of a number of patho-biolog-
ical factors on response to adjuvant therapy. Patient char-
acteristics, type of antibody and scoring system were
similar to those used by others [21]. However, the authors
showed an association between BCL2 positivity and
adverse outcome, which is at variance with most other
published reports and with all others included in the
meta-analysis.
The types of antibodies employed and cut-offs used to
define immunohistochemical positivity also varied
between reports. The effect of each of these is difficult to
assess but could have contributed to the observed hetero-
geneity. Clone 124 was the most commonly used and was
used in the majority of studies where BCL2 was an inde-
pendent predictor of DFS or OS [21,26-
28,31,33,37,39,40]. In contrast, most reports that used
the Dakopatts monoclonal antibody or a polyclonal anti-
body [30,35,36,41] failed to show a statistically signifi-
cant association with DFS or OS, although the direction of
effect was the same. There was little difference in the scor-
ing systems between the studies although the different
cut-off points varied from 10% to 40%. The inclusion of
different combinations of variables in multivariate analy-
ses could also have affected the results of a pooled esti-
mate of the adjusted HRs. The purpose of the meta-
analysis was to establish if the association of BCL2 with
prognosis is independent of other confounders. The
majority of studies included the most important variables
in their analysis, which suggests that the pooled adjusted
estimate of hazard is robust and supports BCL2 as an
independent risk factor. In addition, the similarity
between the HRs observed for BCL2 in both univariate
and multivariate analyses, where both types of analyses
were performed also attest to its prognostic role.
The effect of bias on the meta-analysis should also be con-
sidered. Seventeen eligible reports provided data suitable
for the meta-analysis. Thirty six eligible studies were
excluded, including studies using small series and those
that did not provide minimum data for the pooled analy-
sis. The exclusion of small studies may have minimised
the effect of publication bias – the non-publication of
studies with null results – by not including reports of
small series that are more likely to be published if they
show a positive result. This is supported by our findings
that the HRs reported by smaller studies were systemati-
cally larger than those reported by the larger studies. The
inclusion of only large studies and those that meet mini-
mum quality criteria in the meta-analysis maximised the
chance of the pooled estimate of HR representing the true
HR. Whether we have been able to retrieve all relevant
reports in the literature is unclear. In particular, it is possi-Page 6 of 10
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uating BCL2 as one of multiple markers, but where no
association with outcome was detected. This is perhaps
most likely to occur in studies using TMAs. However, if
large negative studies had been missed, a substantial
degree of publication bias (perhaps a misnomer here as
the data may be published and not retrieved) would have
been detected, whereas we found little evidence for this. It
seems unlikely that missing data bias either through non-
publication, or through failure to identify and retrieve the
data, would have led to a substantial overestimation of
the meta-analysis HR estimates.
The mechanisms through which BCL2 might exert its pro-
tective effect in breast cancer are unclear. Whether it is
consequent upon its role in apoptosis or whether non-
apoptotic functions are involved is unknown. The anti-
apoptotic role of BCL2 is well characterised but its func-
tion in cell cycle control has received less attention. The
latter is well supported by cell line studies that show BCL2
expression delays G1 progression and G1-S transition by
prolonging G0 and is capable of growth inhibitory effects
analogous to those of p53 [24,57]. It is postulated that the
dominance of one of these functions over another may
depend on the cell type and physiology and that the anti-
proliferative effect translates into a tumour suppressor
role in solid epithelial tumours including breast cancer.
Furthermore, it remains to be established if other proteins
e.g. Wnt11 [58] or bcl homologues potentiate the tumour
suppressor role of BCL2 in breast cancer. At least 20 bcl
proteins are known that may act in a synergistic manner,
analogous to the co-operative effect of MYC and BCL2 in
lymphomagenesis.
The therapeutic implication of our findings and how
BCL2 might improve prognostication and/or selection of
patients for treatment remain to be determined. The data
presented here shows that BCL2 has the potential to
improve patient stratification and guide patient manage-
ment. Currently, patients are stratified into different treat-
ment categories based primarily on nodal status, tumour
size, tumour grade, receptor status, patient age and, to a
lesser extent, tumour type. A range of guidelines e.g. St.
Gallen, National Institutes of Health Consensus Develop-
ment Panel, National Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines and prognostic sys-
tems e.g. NPI, ADJUVANT! are used internationally, each
of which combines these features in different ways to
assign patients to risk categories. Recommendations for
systemic treatment are made by some, for example, the
NCCN recommends adjuvant chemotherapy for tumours
> 1 cm in combination, with adjuvant hormonal and traz-
tuzumab depending on receptor status, but not for small
(≤ 5 mm), node-negative invasive tumours or for node-
negative grade 1 tumours between 6 mm and 1 cm. In the
UK, the NPI is used widely to inform decisions on adju-
vant therapy [59,60], however, there is no agreement on
cut-off values. The prognostic value of the NPI is sup-
ported from validation studies but no new prognostic fac-
tors have been shown that add substantially to its use.
Taken in conjunction with previous data, our results sug-
gest that BCL2 could improve the stratification of patients
by the NPI and could separate both the moderate and the
poor prognostic groups each into two prognostic catego-
ries. We showed previously that the prognostic effect of
BCL2 status is maximal in the first five years after a diag-
nosis of breast cancer and wanes thereafter, suggesting
that its utility as a diagnostic adjunct may be limited to
this period. Even if BCL2 were to be used in clinical deci-
sion making, the most appropriate cut-off used to assign
positivity is uncertain. Our previous report [21] indicated
that a dichotomous scoring system using a 10% cut-off
provided the most parsimonious fit for predicting overall
survival using a cox regression analysis, but published
data are insufficient to replicate this.
The number of studies included in the meta-analysis with
different treatment endpoints was too small to perform a
meaningful analysis of its predictive role. However, there
is an emerging consensus that BCL2 plays a key role in
determining response to endocrine therapy and chemo-
therapy [61]. BCL2 is an oestrogen responsive gene
[58,62] and many clinical studies have shown an associa-
tion with favourable response to endocrine therapy
[40,61,63]. BCL2 is a component of the 21-gene signature
used to predict recurrence in tamoxifen-treated ER-posi-
tive node-negative breast cancer and its role is being eval-
uated prospectively in the TAILORx trial [14].
Conclusion
In summary, we have shown that BCL2 is an independent
prognostic marker in two large series of breast cancer [21]
and, here, provide an estimate of the average size of this
association with outcome in a meta-analysis on 16 other
series totalling over 5,000 patients. Using this approach,
we have demonstrated the prognostic power of a single
marker in breast cancer. Large studies, both observational
cohorts and clinical trials, are now urgently needed to test
whether BCL2 and multiple other markers can provide
prognostic information in addition to currently used
standards and also to establish if BCL2 has clinical utility.
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